Company: STAA
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058174
Chunk: 59

Company: STAAR SURGICAL CO
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 59
---
CL procedures. We expect challenges in our China business will continue to pressure our results in 2025, and we are taking steps to best position the company for long-term success. Mr. Jiang has decades of significant and substantive China business and operational experience, and most recently served as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China Region, until his retirement in 2021. During his tenure on our Board, Mr. Jiang has worked closely with our Asia Pacific team to understand the challenges and opportunities in this key region for STAAR. Our Board believes that Mr. Jiang’s knowledge of our Company, business, strategy, and people, combined with his history of success in leadership roles at large multinational pharmaceutical companies in China, make him well suited for this role. As the role is expected to last through the end of fiscal 2025, the Board believed that it was acceptable and appropriate for Mr. Jiang to remain on the Board during his service as an advisor.

Other than the agreement with Mr. Jiang described above, there were no other related person transactions with any Related Persons since December 29, 2023, nor any currently anticipated transaction, requiring disclosure under the SEC’s rules or our Related Person Transaction Policy.

| 2025 Proxy Statement | – 49 – |

SECURITY OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT The following table shows, as of April 22, 2025, information concerning the shares of common stock beneficially owned by each person known by STAAR to be the beneficial owner of more than 5% of our common stock (other than directors and executive officers). This information is based on publicly available information filed with the SEC as of the Record Date.

| Name and Address                    |     | Shares Beneficially Owned |     | Percent of 
 Class(1)   |
| Broadwood Partners, L.P.(2)         
 C/O Broadwood Capital Inc.          
 142 West 57th Street, 11th Floor    
 New York, NY 10019                  |     |                13,545,391 |     | 27.3%      |
| BlackRock, Inc.(3)                  
 50 Hudson Yards                     
 New York, NY  10001                 |     |                 8,222,301 |     | 16.6%      |
| The Vanguard Group(4)               
 100 Vanguard Boulevard              
 Malvern, PA  19355                  |     |